INTRODUCTION {#sec0005}
============

The Huntington's Disease Clinical Trials Corner is a regular section devoted to highlighting ongoing and recently completed clinical trials in Huntington's disease (HD). Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner are listed in [Table 1](#jhd-8-jhd199003-t001){ref-type="table"}.

###### 

Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner

                Trial name       Intervention             Edition
  ------------- ---------------- ------------------------ -------------------
  NCT02519036   IONIS-HTTRx      IONIS-HTT~Rx~^\*^        September 2017(3)
  NCT02215616   LEGATO-HD        Laquinimod               
  NCT02197130   Amaryllis        PF-02545920              
  NCT02006472   PRIDE-HD         Pridopidine              
  NCT03225833   PRECISION-HD1    WVE-120101               February 2018(28)
  NCT03225846   PRECISION-HD2    WVE-120102               
  NCT01795859   FIRST-HD         Deutetrabenazine         
  NCT02481674   SIGNAL           VX15/2503                August 2018(29)
  NCT00712426   CREST-E          Creatine                 
  NCT03761849   GENERATION-HD1   RG6042^\*^               January 2019(30)
  NCT03344601   PACE-HD          Physical activity        
  NCT02535884   HD-DBS           Deep brain stimulation   June 2019
  NCT02453061   TRIHEP3          Triheptanoin             

^\*^IONIS-HTT~Rx~ and RG6042 refer to the same molecule.

In this edition, we highlight the HD-DBS trial (NCT02535884)(1), and the TRIHEP3 trial (NCT02453061)(2). We tabulate all currently registered and ongoing clinical trials in [Tables 2](#jhd-8-jhd199003-t002){ref-type="table"} to [4](#jhd-8-jhd199003-t004){ref-type="table"}. For further details on the methodology used, please refer to the first edition of Huntington's Disease Clinical Trials Corner(3).

###### 

Ongoing pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID              Trial name              Intervention                       Mechanism of Action                                               Population                                  Comparison                         Main outcome                                                                       Study design                                                  Estimated Enrolment                                            Sponsor                                                           Location
  ------------------------ ------------------- ---------------------------- ------------------------------------------------ ------------------------------------------------------------------------ --------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------- -------------------------------------------------------------------------------------------- ---------------------------------------
  NCT03854019^\*^                  --           Dextromethorphan/quinidine       Morphinan/class I antiarrhythmic agent                                HD with irritability                               Placebo               Clinical efficacy at 6 and 13 weeks                                  Randomized, double-blind, placebo-controlled, cross-over trial                                 22                          University of Texas Health Science Center, Cures Within Reach                           USA (single centre)
  NCT03842969^\*^              GEN-EXTEND                 RG6042             Allele- nonselective antisense oligonucleotide                                     HD                                         None              Safety and tolerability at up to 5 years                                                     Open-label extension                                                      950                                               Hoffmann-La Roche                                         USA, Canada, Europe (multi centre)
  NCT03761849                GENERATION-HD1               RG6042             Allele- nonselective antisense oligonucleotide                                     HD                                        Placebo                 Clinical efficacy at 101 weeks                                      Randomized, double-blind, placebo-controlled, parallel trial                                  660                                               Hoffmann-La Roche                                         USA, Canada, Europe (multi centre)
  NCT03787758                      --                    SAGE-718                  NMDA positive allosteric modulator                                           HD                                        Placebo                        Safety at 21 days                                    Randomized, double-blind, placebo-controlled, multiple ascending dose trial                           10                                                Sage Therapeutics                                                         N/S
  NCT03575676                      --                    SOM3355                  VMAT2 inhibitor and *β*1 antagonist                           Early and moderate HD with chorea                         Placebo                       Chorea at 6 months                                           Randomized, double-blind, placebo-controlled, cross-over trial                                 30                                                  SOM Biotech SL                                                 Spain (multi centre)
  NCT03515213                      --                  Fenofibrate                          PPAR*α* agonist                                                     HD                                        Placebo                  Pharmacodynamics at 6 months                                       Randomized, double-blind, placebo-controlled, parallel trial                                  20                                         University of California, Irvine                                         USA (single centre)
  NCT03764215                  Tasigna HD               Nilotinib             Selective Bcr-Abl tyrosine kinase inihbitor                                       HD                                         None        Safety, tolerability and pharmacodynamics at 3 months                                      Open label, multiple ascending dose                                               20                                              Georgetown University                                               USA (single centre)
  NCT03342053               IONIS-HTT~RX~ OLE          ISIS 443139           Allele- nonselective antisense oligonucleotide                                     HD                                         None                 Safety and tolerability at 74 weeks                                                       Open label extension                                                      46                                            Ionis Pharmaceuticals Inc.                                   Canada, Germany and UK (multi-centre)
  NCT03225833                 PRECISION-HD1             WVE-120102             Allele-selective antisense oligonucleotide                                       HD                                        Placebo            Safety and tolerability at 1 and 120 days         Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial           48                                             Wave Life Sciences Ltd.                                       Canada and Poland (multi-centre)
  NCT03225846                 PRECISION-HD2             WVE-120102             Allele-selective antisense oligonucleotide                                       HD                                        Placebo            Safety and tolerability at 1 and 120 days         Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial           48                                             Wave Life Sciences Ltd.                                       Canada and Poland (multi-centre)
  NCT02453061                   TRIHEP 3               Triheptanoin                       Anaplerotic therapy                                                   HD                                     Safflower oil           Pharmacodynamic efficacy at 6 months                                       Randomized, double-blind, controlled, parallel trial                                      100            Institut National de la Santé Et de la Recherche Médicale, Ultragenyx Pharmaceutical Inc     France, Netherlands (multi centre)
  NCT02509793                      --                 Tetrabenazine                         VMAT2 inhibitor                                            HD with impulsivity                                 None            Cognitive and behavioural effects at 8 weeks                                              Single group, open-label trial                                                 20                          University of Texas Health Science Center, and H. Lundbeck A/S                          USA (single centre)
  NCT02481674                    SIGNAL                 VX15/2503                Anti-semaphorin 4D monoclonal antibody                            Late premanifest or early HD                           Placebo           Safety and tolerability at 15 and 21 months                               Randomized, double-blind, placebo-controlled, parallel trial                                  240                                     Vaccinex Inc., Huntington Study Group                                       USA (multi centre)
  NCT02336633                     REVHD                Resveratrol                         Dietary supplement                                                   HD                                        Placebo                Neuroimaging biomarkers at 1 year                                    Randomized, double-blind, placebo-controlled, parallel trial                                  102                                    Assistance Publique - Hôpitaux de Paris                                     France (multi centre)
  EUCTR2013-002545-10-SE     OSU6162Open1309            (-)-OSU616                      Monoaminergic stabilizer              HD, PD, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy       None                    Safety at 3, 6 and 12 months                                                      Single group, open-label trial                                                 240                                            A. Carlsson Research AB                                             Sweden (multi centre)
  NCT00514774                    UDCA-HD                 Ursodiol                              Bile acid                                                        HD                                        Placebo      Safety, tolerability and pharmacokinetics at 35 days                           Randomized, double-blind, placebo-controlled, parallel trial                                  21            Oregon Health and Science University, Huntington Study Group, Huntington Society of Canada                    N/S

N/S, not specified; PD, Parkinson's disease; VMAT2, Vesicular Monoamine Transporter 2. Note: IONIS-HTT~Rx~, ISIS 443139 and RG6042 refer to the same molecule. New trials since the last Clinical Trials Corner are indicated by^\*^.

###### 

Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID    Trial name                   Intervention                             Mechanism of Action                                     Population                              Comparison                       Main outcome                                            Study design                           Esimated Enrolment                                                  Sponsor                                                                       Location
  ----------------- ------------ ---------------------------------------------- ----------------------------------------- ------------------------------------------------------------ ------------------- ----------------------------------------------- -------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  ISRCTN52651778      TRIDENT             Foetal stem cell transplant                       Stem cell therapy                                    Early stage HD                             Usal care                     Safety at 4 weeks                      Randomized, open label, controlled, parallel trial                30                                                    Cardiff University                                                             UK (single centre)
  NCT02728115         SAVE-DH                      Cellavita                                Stem cell therapy                                          HD                                     None                        Safety at 5 years                   Non-randomized, open label, uncontrolled, parallel trial             6                                                        Azidus Brasil                                                             Brazil (single centre)
  NCT03252535         ADORE-HD                     Cellavita                                Stem cell therapy                                          HD                                    Placebo                    Efficacy at 120 days                Randomized, double-blind, placebo-controlled, parallel trial           35                                                       Azidus Brasil                                                             Brazil (single centre)
  NCT03297177            --              Autologous stem/stromal cells           Autologous stem/stromal cell injection                       HD, AD, PD, CBD, MS                             None                        Safety at 5 years                                Single group, open-label trial                         300                     Healeon Medical Inc, Global Alliance for Regenerative Medicine, Regeneris Medical                       USA and Honduras (multi-centre)
  NCT02535884          HD-DBS                        GP DBS                              Deep brain stimulation                             Moderate HD with chorea                     Sham intervention               Efficacy at 12 months                Randomized, double-blind, sham-controlled, parallel trial             50           Heinrich-Heine University, KKS Netzwerk, Medtronic, The George Institute, EHDN, CHDI Foundation, Inc.   Austria, France Germany, Switzerland (multi centre)
  NCT01834053          BMACHC          Bone Marrow Derived MNC transplant                Bone marrow transplant                                  HD with chorea                               None          Cognitive and behavioural effects at 6 months                  Single group, open-label trial                          50                                                 Chaitanya Hospital, Pune                                                         India (single centre)
  NCT02263430            --                          GP DBS                              Deep brain stimulation                                  HD with chorea                         Sham stimulation                Efficacy at 12 months               Randomized, double-blind, placebo-controlled, parallel trial           8                                   Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital                                         China (single centre)
  NCT02252380            --       Magnetic Resonance Guided Focused Ultrasound   Extracranial stereotactic radioablation   HD, ET, HT, PD, WD, dystonia, TD, or orofacial dyskinesias         None               Adverse events after the procedure                        Single group, open-label trial                          10                                                         InSightec                                                               Canada (single centre)

AD, Alzheimer's disease, CBD; Corticobasal Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear cells; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia; WD, Wilson's disease.

###### 

Ongoing non-invasive non-pharmacological clinical trials registered at theWorld Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID         Trial name                        Intervention                                                 Mechanism of Action                                        Population                  Comparison                                                   Main outcome                                                                         Study design                            Esimated Enrolment                                         Sponsor                                                        Location
  ---------------------- ------------ -------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------- ------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------- ---------------------------------------
  ACTRN126180 01717246        --                 Multidisciplinary therapy program              Exercise, cognitive training, lifestyle guidance and social activities             PremanifestHD             Standard of care                                           Feasability and safety                                               Clustered, non-randomized, open label, parallel trial                40                        Edith Cowan University, Deakin University and Lotterywest                        Australia (two centres)
  NCT03417583                 --                Neuropsychiatric treatment protocol                                 Multidisciplinary intervention                       HD with neuropsychiatric symptoms   Standard of care                                   Change in quality of life at 18 months                                          Non-randomized, assessor-blinded, parallel trial                 100                    Vanderbilt University Medical Center and Teva Pharmaceuticals USA                      USA (single centre)
  CTRI/2018/01/011359         --            Repetitive transcranial magnetic stimulation                          Transcranial magnetic stimulation                         Early to moderate HD and PD      Sham stimulation                                             Efficacy at 5 days                                              Randomized, single-blind, placebo-controlled, parallel trial            40                                               Vinay Goyal                                                India (single centre)
  NCT03344601              PACE-HD     Supported structured aerobic exercise training program                               Physiotherapy                                               HD                   Activity as usual   Data completeness, recruitment, retention, safety, adherence, fidelity and acceptability at 12 months      Nested open-label, randomized controlled parallel trial              120                               Cardiff University and CHDI Foundation, Inc                        Germany, Spain and USA (multi centre)
  ACTRN126170 01269325        --                     Swallowing skill training                                       Speech and language therapy                                    HD and ALS                     None                                   Swallowing function and quality of life at 2 weeks                                             Single group, open-label trial                           54                                         University of Canterbury                                      New Zealand (single centre)
  NCT02216474                 --                                tDCS                                              Transcranial magnetic stimulation                           HD or Tourette Syndrome        Sham stimulation                                             Efficacy at 2 weeks                                            Randomized, double-blind, placebo-controlled, cross-over trial          100           Birmingham and Solihull Mental Health NHS Foundation Trust, University of Birmingham            UK (single centre)

AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia.

If you would like to draw attention to specific trials, please feel free to email us at: <f.rodrigues@ucl.ac.uk> and <e.wild@ucl.ac.uk>.

In addition to the above, the published report of the IONIS-HTT~Rx~ trial (NCT02519036) is worthy of mention. The paper reports that monthly intrathecal IONIS-HTT~Rx~/RG6042 -- an antisense oligonucleotide that signals wild-type and mutant huntingtin pre-mRNA to be degraded by RNase H1 -- was safe and well-tolerated, and produced dose-dependent reductions in cerebrospinal fluid mutant huntingtin in early HD patients (4). This is an interesting signal but caution should be exercised as to whether this reduction translates into a clinically significant benefit for people with HD. Further investigation into the effects of this drug are expected from the currently ongoing phase 3 GENERATION-HD1 trial (NCT03761849)(5) and associated studies(6-- 10). These studies will help us better characterize the safety profile of this compound, define the most efficient posology, and understand if it is associated with a clinically relevant benefit, and towards which disease domain.

ONGOING CLINICAL TRIALS {#sec0010}
=======================

A list of all ongoing clinical trials is given in [Tables 2](#jhd-8-jhd199003-t002){ref-type="table"}--[4](#jhd-8-jhd199003-t004){ref-type="table"}.

HD-DBS (NCT02535884) {#sec0015}
--------------------

### Study title {#sec0020}

Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) (HD-DBS)(1).

### Intervention {#sec0025}

DBS of the GP (11) with Medtronic ACTIVA® PC neurostimulator (Model 37601).

### Description {#sec0030}

The HD-DBS trial, sponsored by Heinrich-Heine University, aims to evaluate the efficacy and safety of pallidal DBS in adults (18 or more years of age) with manifest HD (i.e. clinically symptomatic and genetically confirmed \[CAG ≥36\]) and moderate disease stage (defined by the investigators as an Unified Huntington's Disease Rating Scale \[UHDRS\] total motor score \[TMS\] ≥30), chorea (UHDRS chorea score ≥10) and a Mattis Dementia Rating Scale ≥120, comparing with sham stimulation, for motor function.

People with juvenile or predominantly bradykinetic forms of the disease, postural instability, unstable medication in the 6 weeks previous to inclusion, unstable medical or psychiatric comorbidities, coagulopathies and/or increased risk of haemorrhage, implanted pacemaker or defibrillator, pregnant or breast-feeding are not eligible for this study.

This trial is an international, multi-centre, randomized, sham-controlled, double-blind, parallel study. It has 2 study arms: the stimulation group, where participants have stimulation turned on immediately after implantation of the stimulator; and the sham stimulation group, where participants will have a stimulator implanted but it will not be switched on. The study will last 12 weeks, and after that period all participants' stimulators will be turned on.

The trial has already started recruitment, and has a recruitment target of 50 participants, over 4 countries (Austria, France, Germany and Switzerland) and 12 sites.

The primary outcome is the UHDRS TMS at 12 weeks, measured as the difference in the mean change from baseline between the stimulation arm and the sham-stimulation arm. The secondary outcomes include the UHDRS chorea score and the bradykinesia items, the Burke-Fahn-Marsden Dystonia Rating Scale, the Q-Motor choreomotography task, the Mattis Dementia Rating Scale, the Verbal Fluency Test, the Symbol Digits Modalities Test, the Stroop Test, the Hospital Anxiety and Depression Scales and the Snaith Irritability Scale, the Problem Behaviours Assessment Short Form, the Short Form 36 Health Survey, the Clinical Global Impression Scale, and safety.

### Sponsors/funders {#sec0035}

Heinrich-Heine University, KKS Netzwerk, Medtronic, the George Huntington Institute, EHDN and CHDI Foundation.

Comments {#sec0040}
--------

DBS is a relatively well-studied intervention for some manifestations of Parkinson's disease, tremor and dystonia. DBS involves the surgical implantation of electrical electrodes in the deep brain structures, connected via a wire to an implantable pulse generator (i.e. stimulator) usually positioned subcutaneously in the pectoral region. Although the precise mechanisms of action are still not completely understood, this intervention is aimed at interrupting certain neuronal circuits.

In Parkinson's disease DBS is frequently used to minimize levodopa-induced dyskinesia, which has a similar phenomenology to chorea in HD, but a different aetiology. This is accomplished by better controlling the cardinal features of PD, hence reducing the levodopa dose equivalents. There is still uncertainty about whether there is a direct effect of DBS over dyskinesia. In HD, chorea is thought to be caused by the loss of striatal projections to the indirect basal ganglia pathway and consequent thalamic overactivity (11), and although there is a shortage of good-quality evidence, some pilot studies have shown interesting preliminary results when manipulating these circuits with DBS in HD (12, 13).

The scarcity of data so far accumulated precludes drawing conclusions on the safety and efficacy profile of this intervention in HD, but it seems sensible to assume that this population may be susceptible to the same intervention-related adverse events as other tested populations. Disease-specific side effects may be more difficult to predict.

Only large well-controlled prospective controlled studies will allow us to fully understand the efficacy and safety profile of DBS in HD.

TRIHEP3 (NCT02453061) {#sec0045}
---------------------

### Study title {#sec0050}

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (TRIHEP3)(2).

### Intervention {#sec0055}

Triheptanoin oil 1 g/kg/day (14).

### Description {#sec0060}

The TRIHEP3 trial, sponsored by the Institut National de la Santé et de la Recherche Médicale and Ultragenyx Pharmaceutical Inc., aims to evaluate the effects of daily triheptanoin in adults (≥18 years of age) with genetically confirmed manifest HD (i.e. UHDRS TMS between 5 and 40), compared with daily safflower oil. People with a BMI \<18 or \>30, hypersensitivity to triheptanoin, major co-morbidities, history of severe head injury, pregnant or breast-feeding, or on tetrabenazine are not eligible.

TRIHEP3 is an international, multi-centre, randomized, double-blind, controlled, parallel phase 2 trial. It has 2 study arms: the active group, where participants receive triheptanoin oil 1 g/kg/day for 12 months; and the comparator group, where participants receive safflower oil 1 g/kg/day for 6 months and triheptanoin oil 1 g/kg/day for the following 6 months.

The study lasts 12 months, the first half over double-blinded conditions, and the second half as an open-label extension. Recruitment is currently closed and the study is being performed at one centre in France and one centre in the Netherlands. One hundred participants were recruited.

The primary outcomes are pharmacodynamics neuroimaging markers at 3 and 6 months - ^31^P-MRS and volumetric MRI. Secondary outcomes include the UHDRS, comprising the motor, functional and cognitive components, the Problem Behaviours Assessment Short Form, the Short Form 36 Health Survey, adverse events, tolerance and other neuroimaging biomarkers.

### Sponsors/funders {#sec0065}

Institut National de la Santé et de la Recherche Médicale and Ultragenyx Pharmaceutical Inc.

Comments {#sec0070}
--------

Albeit with a low success rate (15), several dietary nutrients with possible effects over metabolic processes have been tested in HD over the years, including d-*α*-tocopherol (16), idebenone (17), co-enzyme Q10 (18), ethyl-eicosapentaenoate (19-- 21), and creatine (22-- 24).

Triheptanoin is an odd-chain triglyceride with anaplerotic properties (i.e. it replenishes biochemical cycles with intermediate metabolites), providing the Krebs cycle with both acetyl-CoA and propionyl-CoA. So far, triheptanoin has been tested for several disorders of the brain metabolism, including pyruvate decarboxylase deficiency, and GLUT1 deficiency where a significant symptomatic effect was demonstrated in a small open-labelstudy (25).

In HD, several lines of evidence support the existence of a dysfunction of the energy metabolism, including the Krebs cycle, oxidative phosphorylation and glycolysis. Two small open-label studies in HD showed that triheptanoin may have the potential to bring peripheral (26) and central nervous system metabolic biomarkers (27) to levels observed in healthy controls. They also anticipate triheptanoin to be well tolerated (26, 27), and overall the cumulative evidence suggests a good safety profile for doses between 1 to2.5 g/kg/day(14).

The TRIHEP3 trial will be completed by the end of 2019 and the results are expected in mid-2020.

CONFLICTS OF INTEREST {#sec0075}
=====================

FBR and EJW were sub-investigators on LEGATO-HD (NCT02215616), IONIS HTT~Rx~ (NCT02519036) and IONIS HTT~Rx~ OLE (NCT03342053), and are sub-investigators on the Roche GENERATION-HD (NCT03761849), Roche Natural History Study (NCT03664804) and Roche GEN-EXTEND (NCT03842969) trials, and EJW was a sub-investigator on the Amaryllis (NCT02197130). EJW is the chief investigator of the Roche GEN-PEAK trial (NCT04000594) and FBR is a sub-investigator. JJF was principal investigator on LEGATO-HD and on a trial of ethyl-eicosapentanoate in Huntington's disease. The authors did not make use of confidential or privileged information: all materials included in this manuscript were collected from publicly available sources. FBR has provided consultancy services to GLG. EJW has participated in scientific advisory boards with Hoffmann-La Roche Ltd, Ionis, Shire, GSK, Wave Life Sciences, PTC Therapeutics, Takeda and Mitoconix. All honoraria were paid through UCL Consultants Ltd, a wholly owned subsidiary of UCL. Their Host Institution, University College London Hospitals NHS Foundation Trust, has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals. Hoffman La Roche Ltd has supported UCL with research funding for EJW. In view of the support to both regular authors from Hoffman-La Roche Ltd, JJF was invited to be a co-author to ensure the sections on the Ionis/Roche program were suitably balanced.

JJF received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic. He received consultancy fees from GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals. He is employed by Faculdade de Medicina de Lisboa and CNS - Campus Neurológico Sénior. He also participated in advisory boards for Bial and expert testimony to Novartis.

The authors are supported by CHDI Foundation, Inc. (salary support to FBR and EJW).
